Genmab Business Model Canvas

Genmab designs and optimizes differentiated antibody therapeutics using proprietary platforms like DuoBody and HexaBody, running high – throughput screening and molecular engineering to boost binding and effector functions; R&D spend was DKK 5.6bn in 2024, reflecting sustained investment to keep pace with fast – moving biotech and support a pipeline of 20+ clinical programs as of Dec 31, 2024.

Genmab runs global clinical trial management-planning, executing, and overseeing multicountry studies to win regulatory approvals; in 2024 Genmab reported 30+ active trials and invested €540M in R&D, ensuring data integrity and patient safety across sites. Success here moves candidates from lab to market, cutting time-to-market and protecting potential peak sales (tepotinib-like assets target >€1B lifetime sales).

Genmab's core tech-DuoBody, HexaBody, DuoHexaBody, HexaMix-drives bispecific and enhanced-antibody designs that conventional mAbs can't match; these platforms underpinned 2025 revenue-linked collaborations totaling over $2.1B in upfronts and milestones and support a pipeline with 10+ clinical programs, including marketed product TEPEZZA royalties and multiple partnered candidates in Phase 2-3.

Genmab's world-class scientific workforce-about 1,900 employees as of end-2024, with >60% in R&D-provides the intellectual capital for antibody discovery, leveraging deep expertise in immunology, molecular biology, and oncology to drive a pipeline of 30+ programs and quarterly R&D spend of ~DKK 2.1bn (FY2024). Retaining this talent is critical to sustain innovation velocity and solve complex biological challenges that underpin future licensing and revenue growth.

Genmab's next-generation bispecific antibodies bind two distinct antigens or epitopes, boosting tumor cell kill and immune engagement where single-target drugs fail; Janssen-partnered drug epcoritamab showed 60-70% overall response rates in relapsed diffuse large B-cell lymphoma trials (2024 data). These precision biologics expand addressable market-Genmab reported DKK 19.9bn revenue in 2024-offering physicians more potent, targeted options with scalable royalty and milestone economics.

Genmab's engineered antibodies stimulate stronger immune responses than standard monoclonals, driving improved response rates and median overall survival in trials-e.g., bispecifics showing ORR increases up to 40% versus historical controls and median OS gains of several months (2024 pooled oncology data). This efficacy edge supports premium pricing and faster uptake, helping Genmab capture oncology market share in segments forecasted to grow ~8-10% CAGR through 2028.

Genmab maintains deep, multi-year B2B strategic partnerships with big pharma-e.g., Janssen and AbbVie-using joint governance committees and shared milestones; as of 2025 Genmab reported collaboration revenue of DKK 3.4bn in 2024 and retains double-digit royalty upside on key products, so trust and transparent reporting are essential for successful co-commercialization.

Genmab sustains deep ties with Key Opinion Leaders and clinicians via peer-reviewed exchanges and participation in 420+ clinical sites across 30 countries (2025 data), which boosted daratumumab-related treatment adoption and supported $1.2bn royalty revenue in 2024; expert feedback drives protocol tweaks and pipeline prioritization, shortening Phase II timelines by ~18% on recent programs.

Genmab leverages partners like Janssen and AbbVie, whose combined oncology sales forces number several thousand reps (Janssen ~20,000 global commercial staff; AbbVie ~47,000 total employees with a large commercial footprint), enabling Genmab to access established oncology networks and accelerate uptake without building its own global salesforce.

In select territories and for key antibodies Genmab deploys specialized sales and medical affairs teams, retaining higher margins-direct commercial operations raised product gross margin by an estimated 8-12 percentage points versus partner-led sales in 2024-and building its own market identity; expanding these internal teams is a strategic priority to increase independence as Genmab targets direct launches for 3-5 products by 2028.

Large-cap pharmaceutical corporations license Genmab's antibody engineering and enter co-development deals to strengthen oncology pipelines; in 2024 Genmab reported cumulative partnership revenue exceeding €2.3 billion, driven by upfronts and milestone payments. These B2B partners supply steady long-term royalty streams-Genmab earned €620 million in royalties and product revenue in 2024-making this segment central to cash flow and R&D leverage.

Specialized oncologists, oncology nurses, and hospital systems-who prescribe and administer Genmab's antibodies-drive uptake; they demand peer – reviewed clinical data, real – world evidence, and practical protocols (e.g., 2024 trials showing 30-45% response rate in target indications) plus training and infusion support. Meeting these needs is critical for commercial success: provider adoption correlates with faster revenue ramp and lower time – to – peak sales for biologics (median 3-5 years post – approval).

Genmab spends the largest share of its operating budget on R&D-DKK 5.0 billion in 2024 (48% of Opex), funding antibody discovery, platform upkeep, lab consumables, advanced equipment, and salaries for ~1,500 research staff; ongoing R&D is critical to sustain the pipeline and competitive lead.

Running global, multi-center clinical trials forces Genmab to absorb high costs for patient recruitment, monitoring, and data analysis; Phase 3 programs can exceed $100-300M per trial and often span 3-7 years, increasing follow-up and site-management expenses. Genmab offsets much of this via partner cost-sharing-e.g., its Janssen collaboration has historically covered large portions-yet independent trials still represent multi-hundred – million dollar capital commitments on the balance sheet.

Genmab earns double-digit percentage royalties on net sales of partner – marketed drugs, chiefly Darzalex with Janssen; royalties totaled about DKK 9.6 billion (≈USD 1.4 billion) in 2024, up ~5% year – on – year. This high – margin, recurring revenue scales with global Darzalex sales and remains the main driver of Genmab's profitability and cash flow stability.

Genmab earns one-time milestone payments when partners hit development, regulatory, or commercial triggers; these have ranged from low – millions to >300 million USD for major approvals (for example, similar oncology deals saw regulatory milestones of ~100-300M in 2021-2024). These periodic cash infusions fund internal R&D and reduced dilution, with milestone receipts helping finance pipeline advancement and trials.